TenQ

The Novavax story

Novavax is a vaccine developer shifting toward licensing its Matrix-M technology, with the question of whether Sanofi royalties and partner demand can support a smaller operating base.

Novavax stock reportTenQ Score 9/36 · every chart and check from its filings
  • $11.26share price, last close
  • $1.9Bmarket value
  • 9/36TenQ Score checks passed

The story in brief

  • Product demand improved. In the quarter to June 2026, product sales rose 76% to $19 million, but total revenue fell 76% to $57 million against a comparison boosted by milestone payments.
  • Commercial costs declined. In the quarter to June 2026, SG&A expenses declined 39% to $27 million as Novavax transferred lead commercial activities to Sanofi and reduced its administrative costs.
  • Sanofi timing matters. Initiation of Sanofi's Phase 3 COVID-19 and influenza combination trial in the U.S. or European Union would trigger a $125 million payment, but regulatory discussions on timing remained underway in August 2026.

What drives the business

  • Novavax's strategy centers on licensing its protein-based vaccine technology and Matrix-M immune-boosting adjuvant, with Sanofi leading Nuvaxovid commercialization while Novavax retains certain existing supply commitments.
  • The Sanofi agreement makes Novavax eligible for royalties in the high teens to low twenties percent on Nuvaxovid and licensed combination vaccine sales, alongside development, manufacturing transfer and launch milestones.
  • The January 2026 Pfizer agreement licenses Matrix-M for up to two infectious disease areas, with a $30 million upfront payment, potential development and sales milestones of up to $500 million, and royalties.
  • Serum Institute of India manufactures the University of Oxford's R21/Matrix-M malaria vaccine, available in 24 countries as of February 2026, and pays Novavax for adjuvant supplies and royalties.
  • Takeda licenses the COVID-19 vaccine in Japan and purchases Matrix-M, with the amended agreement providing royalties in the mid to high-teen percentages rather than a share of operating profits.

What the price assumes

At $11.37, the reverse DCF cannot measure an implied growth rate because free cash flow and operating earnings are both negative, leaving the price dependent on future profits.

Novavax generated $414 million in revenue over the last twelve months, with revenue growth of -61.6% and free cash flow of -$42 million.

Its 4.5x price to sales exceeds the TenQ check's bar of under 2.5x, although its sales valuation is lower than its own history.

What could change the story

  • Milestones and contract accounting complicate revenue comparisons, including $575.7 million recognized as product sales in 2025 after termination of the Canada supply agreement released previously recorded obligations.
  • Sanofi's regulatory progress and commercial execution affect both milestone timing and royalties, and Novavax excluded Sanofi supply sales, royalties and milestones from its 2026 revenue framework because forecasts were unavailable.
  • Under the Australia supply agreement, up to $92.5 million of deferred revenue may become refundable if regulatory approval and delivery deadlines are missed.
  • Cash and short-term investments of $719 million exceed total debt of $291 million, but negative equity and an operating margin of -56.6% limit the strength suggested by that liquidity.
  • Shares increased 121.4% over the last three years, while stock-based pay totaled $32 million over the last twelve months, making dilution another constraint on results per share.

What to watch next

  • Novavax's raised 2026 framework calls for Adjusted Total Revenue of $235 million to $275 million, excluding Sanofi supply sales, royalties and milestones, so separate disclosure of those categories will clarify the partnership's contribution.
  • Its 2026 combined R&D and SG&A expense guidance is $370 million to $410 million, while the non-GAAP range remains $310 million to $340 million after partner reimbursements.
  • The next Sanofi updates should establish combination trial timing and progress toward manufacturing technology transfer, expected in mid-2027 and linked to a $75 million milestone payment.
  • Novavax also expects its C. difficile vaccine program could enter the clinic as early as 2027, making manufacturing and regulatory progress relevant measures of its internal pipeline.

Sources

Back to the NVAX report